Ameet Nagpal, MD
Pain Medicine · Charleston, SCNPI 1982830758
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Averitas Pharma Inc. at 36.7% of the total. Reporting peaked in 2024 at $3,119 and has fallen 74.8% since, to $785 in 2025.
Across 78 payments — averaging $111.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Averitas Pharma Inc.$3K
- GRT US Holding, Inc.$2K
- Medtronic$815
- Nevro Corp.$634
- Abbott$589
- MML US, Inc.$351
- plus $1K from 9 others
What the payments were for
- Consulting fees$2,00023%
- Speaking & faculty fees$2,78832%
- Food & beverage$3,94645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Averitas Pharma Inc. | 8 | $3,207 |
| GRT US Holding, Inc. | 4 | $2,105 |
| Medtronic(2 entities) | 14 | $815 |
| Nevro Corp. | 18 | $634 |
| Abbott | 7 | $589 |
| MML US, Inc. | 4 | $351 |
| SPR Therapeutics, Inc | 4 | $350 |
| Boston Scientific | 4 | $186 |
| Nalu Medical, Inc. | 1 | $114 |
| Tersera Therapeutics LLC | 5 | $111 |
| Relievant Medsystems, Inc. | 4 | $111 |
| Avanos Medical | 1 | $57 |
| Ipsen Biopharmaceuticals, Inc | 1 | $49 |
| AbbVie | 2 | $29 |
| Biogen | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$5,064
- Proclaim Family of SCS IPGs$356
- Senza Spinal Cord Stimulation System$265
- Intracept$143
- Accurian$132
- INTELLIS$114
- Nalu Neurostimulation System$114
- SYNCHROMEDII$108
- ReActiv8$107
- INTELLIS ADAPTIVESTIM$107
How this compares
$8,734 in reported general payments places this provider in the 75th percentile of 92 pain medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 85 | $2,142 |
| Celecoxib | 48 | $856 |
| Duloxetine Hcl | 44 | $683 |
| Gabapentin | 48 | $367 |
| Amitriptyline Hcl | 33 | $200 |
| Tizanidine Hcl | 19 | $106 |
| Meloxicam | 12 | $20 |
| Alprazolam | 25 | $13 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Charleston
- Andrew MendelsonCharleston$19K
- Martin BurkeCharleston$11K
- Justin WikleCharleston$5K
- Robert SullivanCharleston$5K
- Derrick RandallCharleston$3K
- Edward TavelCharleston$2K
- Michael HillegassCharleston$2K
- Meron SelassieCharleston$2K
- Ann FoxxCharleston$1K
- Phillip SmithGreenville$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.